TMCnet News
Research and Markets: Asia Pacific Type 2 Diabetes Therapeutics Markets to 2020Research and Markets (http://www.researchandmarkets.com/research/vrv7fk/type_2_diabetes) has announced the addition of the "Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020" report to their offering. In 2013, the value of the type 2 diabetes therapeutics market in APAC countries was an estimated $6.5 billion, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% between 2013 and 2020 to $10.5 billion This strong growth is due to the anticipated approval of products in relatively novel treatment classes, such as Glucagon-Like Peptide-1 (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors, and Sodiu Glucose Transporter-2 (SGLT-2) inhibitors, as well as the growth of the prevalence population in the APAC region, particularly in India and China. This report provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by a team of industry experts. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Type 2 Diabetes Market to 2020 - Pipeline Products 5 Market Forecast to 2020 6 Deals and Strategic Consolidations 7 Appendix Companies Mentioned
For more information visit http://www.researchandmarkets.com/research/vrv7fk/type_2_diabetes
|
